October accrual is on pace to be the highest month on record. Since July 1, TMIST has enrolled more patients than all other National Cancer Institute clinical trials combined. An unheard-of number (nearly 20%) are Black and African American women. Drs. Etta Pisano and Mitch Schnall provide the latest status of the trial and discuss its continuing relevance
This phase II study, led by Dr. Bonnie Ky, aims to generate the necessary data to inform a phase III randomized controlled trial with the potential to make a significant public health impact
This is the only study that is currently designed to test the ability to improve long-term outcomes by refining early-setting triple-negative breast cancer chemotherapy without exposing ALL patients to more toxicity preoperatively
In the fifth month of restrictions due to COVID-19, member institutions pivot back to focus on general health care; clinical trial enrollments begin to rise back up to pre-pandemic levels; Fall 2020 Group Meeting to be virtual; EA holds first meeting of planned move to an anti-racist agenda
Strong EA research presence at ASCO 2020; the horrific killing of George Floyd; health equity and diversity in the field of oncology; the need for EA to participate in changing a specifically anti-racist culture and increase diversity and inclusion